Synergic Therapeutic Potential of PEA-Um Treatment and NAAA Enzyme Silencing In the Management of Neuroinflammation
Laboratory studyHumansOther animals
- Design
- Laboratory study
- Subjects
- Human SH-SY5Y neuronal cells and human Mo3.13 oligodendrocyte cells, rat C6 glioma cells and mouse BV-2 microglia, with and without NAAA gene silencing, stimulated with LPS (1 microgram/mL) and interferon gamma (100 U/mL)
- Dose used in the study
- Ultramicronised palmitoylethanolamide 1, 3 and 10 micromolar in culture
- Duration
- Not stated in the abstract
- What was measured
- Cell viability by MTT; iNOS and COX-2 protein by Western blot in control and NAAA-silenced cells.
What the authors reported
Ultramicronised PEA at 3 and 10 micromolar protected viability in all cell lines after inflammatory stimulation. Combining NAAA silencing with PEA treatment reduced iNOS and COX-2, which the authors describe as adequate to counter neuroinflammation in these cells.
Limits of this study
A cell culture study; it cannot show effect in people or animals treated in practice. No numbers for the marker changes are given in the abstract. Salvatore Cuzzocrea holds patents with Epitech Group, which makes ultramicronised PEA; the authors say these are unrelated to the study.
Source
PubMed 33050589 · doi:10.3390/ijms21207486
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.